NCT01906658 - A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

Repository corticotropin injection

Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks

Trial Locations (17)

15212

Questcor Investigational Site, Pittsburgh

17033

Questcor Investigational Site, Hershey

30322

Questcor Investigational Site, Atlanta

32224

Questcor Investigational Site, Jacksonville

33136

Questcor Investigational Site, Miami

33612

Questcor Investigational Site, Tampa

35233

Questcor Investigational Site, Birmingham

38104

Questcor Investigational Site, Memphis

55905

Questcor Investigational Site, Rochester

66160

Questcor Investigational Site, Kansas City

68506

Questcor Investigational Site, Lincoln

75214

Questcor Investigational Site, Dallas

77030

Questcor Investigational Site, Houston

78229

Questcor Investigational Site, San Antonio

85018

Questcor Investigational Site, Phoenix

94115

Questcor Investigational Site, San Francisco

94305

Questcor Investigational Site, Stanford